---
title: "Obefazimod (ABX464) in Ulcerative colitis: ABX464-104"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: ABX464-104. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 64 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence/abx464-104"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: ABX464-104

<a id="heading-3.1.5"></a>

## 3.1.5 ABX464-104

<a id="heading-3.1.5.1"></a>

### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov record

> “A phase 2b study to evaluate the long-term efficacy and safety study of ABX464 50mg as maintenance therapy in patients with moderate to severe Ulcerative Colitis.”
> “A Phase 2b, Open-label, Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.1-2"></a>

#### Objectives stated in the published report

> “The objectives of the OLM study were to assess the long-term safety and efficacy of obefazimod 50 mg od.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.1-3"></a>

#### Primary objective in the protocol

> “The primary objective of the study is to assess in all patients the long-term efficacy of ABX464 given at 50 mg QD on clinical remission at week 48 compared to the induction study (ABX464-103) baseline (ISB).”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.1-4"></a>

#### Selected secondary objectives in the protocol, including cardiac function

> “To evaluate the proportion of patients with glucocorticoid-free clinical remission at week 48.”
> “To evaluate the effect of ABX464 50 mg QD on patients’ quality of Life (QoL) measured by the Inflammatory Bowel Disease Questionnaire (IBDQ) at week 24 and week 48 compared to BOLS.”
> “To evaluate the long-term safety profile of ABX464 50 mg QD.”
> “To evaluate the effect of ABX464 on cardiac function as assessed through echocardiograms.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="heading-3.1.5.2"></a>

### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

#### Study dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2020-01-13”
> “Primary Completion (Actual) 2023-02-23”
> “Study Completion (Actual) 2023-02-23”
> “Results First Posted 2025-04-27”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.2-2"></a>

#### Registered locations

> “This study has 120 locations”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.2-3"></a>

#### Centers and countries in the published report

> “Patients were enrolled at 69 study centers in 14 countries (Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Italy, Poland, Serbia, Slovakia, Slovenia, Spain, and Ukraine).”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.2-4"></a>

#### Planned sites in the protocol

> “Patients will be enrolled in 69 sites located in Europe, US and Canada.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.2-5"></a>

#### Conduct in Ukraine during the war

> “The Phase 2b 12-month assessment was carried out in all the Ukrainian patients before the war broke out and these patients are therefore included in the one-year maintenance results that were reported on April 6, 2022. Ukrainian patients who completed the two-year Phase 2b maintenance trial have been transitioned to the long-term safety and efficacy trial that is still on-going.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.5.3"></a>

### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Model description | “open-label, follow-up study” |
| Masking | “None (Open Label)” |
| Phase | “Phase 2” |
| Enrollment (actual) | “217” |

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.3-2"></a>

#### Open-label design described in the ClinicalTrials.gov record

> “This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (o.d) at 50 mg in subjects who have been previously enrolled in the ABX464-103 clinical study (induction study) and who are willing to continue their treatment.”
> “All subjects will receive ABX464 given at 50mg o.d regardless of their previous treatment and dose received in the ABX464-103 study (i.e. ABX464 100mg, ABX464 50mg, ABX464 25mg or Placebo).”
> “Subjects will be treated with ABX464 for an overall period of 48 weeks. Subjects will be followed up on a monthly basis.”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.3-3"></a>

#### Entry regardless of induction response, continuation to week 96, and visit schedule

> “Patients who had completed the induction study phase and who were willing to continue treatment could enter the OLM and receive treatment with obefazimod 50 mg od, regardless of the patient’s clinical response or randomized treatment (placebo or obefazimod 25, 50, or 100 mg od) during induction (Figure 1).”
> “After week 48, patients who had shown clinical response (defined as a decrease in MMS ≥2 points and ≥30% from baseline (induction), plus a decrease in rectal bleeding subscore [RBS] ≥1 or an absolute RBS ≤1) were eligible for continued participation in the extension for a total period of 96 weeks.”
> “From day 1 onwards, patients were seen at the investigational site every 4 weeks up to week 48, then at weeks 60, 72, 84, and 96; flexible sigmoidoscopy with rectal and/or sigmoidal biopsies was performed at weeks 48 and 96 (both central and blinded reading of endoscopies were assessed).”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.3-4"></a>

#### Safety follow-up, exit for disease progression, and roll-over to ABX464-108 in the protocol

> “Patients will be treated for a maximum of 96 weeks in this maintenance study. After the treatment period, patients will be followed for 4 additional weeks for safety purposes. Alternatively, eligible subjects willing to continue study treatment will be offered to take part in a long term follow up safety study (ABX464-108) at the end of treatment (ie Week 96).”
> “During the open label maintenance phase, in the event of clinical progression of the disease, defined as at least a 2-point increase from the screening partial Modified Mayo Score (pMMS) with a pMMS ≥ 4 confirmed by an endoscopy sub score of 2 points or higher, the patient will exit the study.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.3-5"></a>

#### Data and Safety Monitoring Board and Independent Cardiovascular Safety Committee

> “A Data and Safety Monitoring Board (DSMB) with expertise and experience in the management in UC will review the safety of the trial every 2 months during the entire study period.”
> “An Independent Cardiovascular Safety Committee (ICVSC), comprised of 3 cardiologists with experience from drug development, will be formed as detailed in the Charter.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.3-6"></a>

#### Echocardiography added after enrollment was complete

> “Since enrolment is completed at the time of this amendment, drug-free baseline measurements are not available. Echocardiography will be performed at the earliest opportunity (Week 24 or Week 48 or Week 72) and will be repeated every six months.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="heading-3.1.5.4"></a>

### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

> “Patients must have completed the 16-week induction treatment period (ABX464-103);”
> “Patients are able and willing to comply with study visits and procedures as per protocol;”
> “18 Years to 75 Years (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.4-2"></a>

#### Criteria for a second 48 weeks of treatment

> “Criteria that should be met by patients at week 48 to be eligible for 48 additional weeks of study treatment.”
> “Patients should be in clinical response. Clinical response is defined as: a reduction in Modified Mayo Score ≥ 2 points and ≥ 30 % from baseline (induction) with an accompanying decrease in rectal bleeding sub-score ≥ 1 point or absolute rectal bleeding sub-score ≤ 1 point.”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.4-3"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

> “Patients who had major protocol deviation(s) in the induction study;”
> “Patients who permanently discontinued study the treatment in induction study (ABX464-103) because of an adverse event (AE) regardless of relatedness to investigational product;”
> “Patients who are participating or plan to participate in other investigational studies (other than induction study) during the study.”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.4-4"></a>

#### Induction population described in the published report

> “The study design and results from the induction trial, as well as the eligibility and exclusion criteria for patients aged 18–75 with moderate-to-severely active UC, have been reported previously.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="heading-3.1.5.5"></a>

### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

#### Intervention in the ClinicalTrials.gov record

> “All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks.”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.5-2"></a>

#### Administration in the protocol

> “Patients will be treated with a daily dose of 50mg of ABX464. Patients will receive 1 capsule every day.”
> “All patients will be orally dosed in a fed condition (regular meal) with a glass of water.”
> “No intra-patient dose escalation/dose adjustment are allowed.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.5-3"></a>

#### Allowed and prohibited concomitant medications and corticosteroid tapering

> “Allowed concomitant medications were continued from the baseline of the induction trial. These included corticosteroids (CS; ≤20 mg per day of prednisone or prednisone equivalent, ≤5 mg per day of beclomethasone dipropionate, or ≤9 mg per day budesonide MMX), oral 5-ASA, immunosuppressants such as azathioprine and 6-mercaptopurine, and antidiarrheals.”
> “The use of biologics (eg, TNF-α inhibitors, vedolizumab, ustekinumab), JAK inhibitors, cyclosporin, and tacrolimus was prohibited during the study. At the start of the OLM study, CS-tapering was recommended in all patients but was not mandatory.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="heading-3.1.5.6"></a>

### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

#### 3.1.5.6.1 Rationale for Using Clinical Remission by Modified Mayo Score as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

##### Registered primary outcome measure

> “Proportion of Patients With Clinical Remission at Week 48 Compared to Baseline of Induction Study (ABX464-103)”
> “Clinical remission (based on the Mayo scoring system) is defined as: a rectal bleeding sub-score = 0, and an endoscopy sub-score ≤1 (excluding friability), and at least 1-point decrease in stool frequency sub-score from baseline to achieve a stool frequency sub-score ≤1”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.6.1-2"></a>

##### Primary endpoint and remission definition in the protocol

> “Proportion of patients with clinical remission at week 48 compared to induction study baseline.”
> “Clinical remission, based on the Mayo Scoring system, is defined as stool frequency sub score = 0 or 1 and rectal Bleeding sub score = 0 and endoscopy sub score = 0 or 1 (modified to exclude friability).”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.6.1-3"></a>

##### Efficacy endpoints and definitions in the published report

> “Endpoints included rate of clinical remission (defined as stool frequency subscore [SFS] ≤1 and rectal bleeding = 0 and endoscopic score of 0 or 1), rate of clinical response (defined as a decrease from baseline in MMS ≥2 points and ≥30% from baseline, plus a decrease in RBS ≥1 or an absolute RBS ≤1), rate of endoscopic improvement (endoscopic subscore ≤1), rate of endoscopic remission (endoscopic subscore = 0), change from baseline of OLM study by visit up to week 96 for stool frequency, and fecal calprotectin (FCP).”
> “CS-free status, defined as the cessation of CS for at least 12 weeks prior to each assessment time point in this analysis, was evaluated for efficacy outcomes at weeks 48 and 96 within the subgroup of patients receiving concomitant CS at the induction baseline.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.6.1-4"></a>

##### Glucocorticoid-free clinical remission defined in the protocol

> “Glucocorticoid-free clinical remission is defined as clinical remission in addition to not requiring any treatment with glucocorticoids for at least 8 weeks prior to week 48.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.6.1-5"></a>

##### Registered secondary outcome: clinical response definition

> “Proportion of patients with clinical response at week 48 Clinical response is defined as: a reduction in Mayo Score ≥ 3 points and ≥ 30 % from baseline with an accompanying decrease in rectal bleeding sub-score ≥ 1 point or absolute rectal bleeding sub-score ≤ 1 point.”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.6.1-6"></a>

##### Endoscopic improvement and fecal calprotectin as treatment targets

> “Endoscopically determined improvement in mucosal appearance has been associated with more favorable long-term outcomes in patients with UC.”
> “FCP levels below 150 µg/g typically indicate remission with a high degree of accuracy according to Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) recommendations.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="heading-3.1.5.7"></a>

### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

#### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

##### No sample size calculation in the protocol

> “This study is an open label extension study. Sample size calculation is therefore not applicable.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.7.1-2"></a>

##### Participants enrolled and analyzed in the published report

> “Of the 222 eligible patients who completed the induction trial, 217 (97.7%) were enrolled in the OLM study (Figure S1).”
> “The primary analysis set for efficacy was the full analysis set (FAS, N = 217), and analysis of safety parameters was carried out using the safety analysis set (SAF, N = 217).”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.7.1-3"></a>

##### Participants analyzed in the posted results

| Measure | Quoted record |
| --- | --- |
| Enrollment (actual) | “217” |
| Overall number of baseline participants | “217” |
| Overall number of participants analyzed, clinical remission at week 48 | “217” |

Source: [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results)

<a id="heading-3.1.5.7.2"></a>

#### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

##### Full analysis set, safety analysis set, baseline, and nonresponder imputation in the published report

> “The FAS included all patients who received at least 1 dose of obefazimod 50 mg and had a baseline of OLM data for at least 1 efficacy variable; the SAF included all patients who received at least 1 dose of obefazimod 50 mg.”
> “Baseline of OLM was defined as the last non-missing measurement after induction (week 8 or 16) taken prior to the first dose of obefazimod 50 mg of the OLM study.”
> “The proportions of patients in clinical remission, clinical response, with endoscopic improvement, or endoscopic remission were summarized descriptively using nonresponder imputation (NRI) analysis at weeks 48 and 96 (patients with missing data were imputed as nonresponders).”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.7.2-2"></a>

##### Analysis sets in the protocol

> “The Safety dataset (SAF population) is defined as those patients included in the study, who have received at least one dose of the study treatment.”
> “The Full Analysis dataset (FAS population) is defined as those patients included in the study, who have received at least one dose of the study treatment, and who have at least one efficacy baseline data.”
> “The Per Protocol dataset (PP population) is defined as those patients of the FAS population without any major protocol deviation.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.7.2-3"></a>

##### Two baselines and missing data rules in the statistical analysis plan

> “ISB (Induction Study Baseline) is the baseline measurement for the Induction (ABX464-103) study.”
> “BOLS (Baseline of Open Label Study) is the Day 113 (Week 16) measurement of the Induction (ABX464-103) study.”
> “Patients discontinued prior to Week 96 are considered as non-responders at Week 96 i.e. not achieving clinical endpoint at Week 96. LOCF method is used to impute completers (not discontinued but missing Week 96 assessment) by carrying forward the results from Week 48.”

Source: [Abivax ABX464-104 statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/SAP_001.pdf)

<a id="topic-3.1.5.7.2-4"></a>

##### Descriptive statistics and interim analysis at week 48

> “Descriptive statistics were presented for all efficacy and safety variables.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

> “An interim analysis will be performed when all the subjects reach Week 48 visit.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="heading-3.1.5.8"></a>

### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

#### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

##### Participant flow in the posted results

| Measure | Participants |
| --- | --- |
| Started | “217” |
| Completed | “164” |
| Not completed | “53” |
| Adverse event | “16” |
| Death | “1” |
| Lack of efficacy | “3” |
| Lost to follow-up | “1” |
| Other reason (e.g., Ukraine Crisis) | “10” |
| Physician decision | “4” |
| Pregnancy | “4” |
| Withdrawal by subject | “14” |

Source: [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results)

<a id="topic-3.1.5.8.1-2"></a>

##### Discontinuations by year in the published report

> “Of 222 eligible patients, 217 were enrolled and 164 (75.6%) completed week 96 of the OLM study.”
> “Thirty of 217 (13.8%) discontinued prior to week 48, 6 patients did not meet eligibility criteria for the second year of treatment (did not achieve clinical response at week 48 or were unwilling to continue) and 17/181 (9.4%) patients discontinued between weeks 48 and 96. All discontinuations were considered as treatment failures for the NRI analysis of efficacy at weeks 48 and 96.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.1-3"></a>

##### Enrollment and completion in the Form 20-F

> “Of the 222 patients who completed our 16-week Phase 2b induction trial, 217 patients (98%) enrolled in the subsequent open-label maintenance trial to evaluate the long-term safety and efficacy profile of obefazimod for up to two years, irrespective of treatments or treatment outcome during the induction phase.”
> “Of the patients included in the maintenance trial, 164 patients (76%) completed two years of once-daily oral dosing with 50 mg obefazimod.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.5.8.2"></a>

#### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

##### Demographic and baseline characteristics in the published report

| Characteristic | Total (N = 217) |
| --- | --- |
| Age, years, mean (SD) | “42.1 (13.8)” |
| Male, n (%) | “133 (61.3)” |
| Female, n (%) | “84 (38.7)” |
| Obefazimod 25 mg during induction, n (%) | “58 (26.7)” |
| Obefazimod 50 mg during induction, n (%) | “51 (23.5)” |
| Obefazimod 100 mg during induction, n (%) | “53 (24.4)” |
| Placebo during induction, n (%) | “55 (25.3)” |
| Naïve to biologics or JAK inhibitors, n (%) | “119 (54.8)” |
| Inadequate response to biologics or JAK inhibitors, n (%) | “98 (45.2)” |
| Inadequate response to 2 or more biologics or JAK inhibitors, n (%) | “70 (71.4)” |
| Concomitant corticosteroids, n (%) | “120 (55.3)” |
| Concomitant 5-ASA, n (%) | “159 (73.3)” |
| Fecal calprotectin, µg/g, mean (SD) | “900.1 (1574.5)” |

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.2-2"></a>

##### Baseline characteristics described in the text of the published report

> “At baseline of OLM, the mean age was 42.1 years; 61.3% of patients were men; 162 patients were randomized to 1–3 doses of obefazimod and 55 patients to placebo in the induction trial.”
> “At baseline of OLM, 98 patients (45.2%) had prior inadequate response to biologics or JAK inhibitors (70 of these 98 (71.4%) patients had inadequate response to ≥2 biologics or JAK inhibitors), 119/217 patients (54.8%) were naive to biologics or JAK inhibitors and 120/217 patients (55.3%) were using concomitant corticosteroids (Table 1).”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.2-3"></a>

##### Race and ethnicity not collected, and participants by country in the posted results

> “Race and Ethnicity were not collected from any participant.”

Source: [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results)

| Country | Participants |
| --- | --- |
| Poland | “63” |
| Ukraine | “30” |
| France | “24” |
| Hungary | “17” |
| Italy | “17” |
| Canada | “5” |

Source: [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results)

<a id="heading-3.1.5.8.3"></a>

#### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

##### Clinical and endoscopic outcomes at weeks 48 and 96, all participants (nonresponder imputation)

> “Among the 217 patients who enrolled in the OLM study and received 50 mg od oral dosing with obefazimod, 177/217 (81.6%) and 158/217 (72.8%) achieved clinical response at weeks 48 and 96, respectively, and 119/217 (54.8%) and 114/217 (52.5%) patients achieved clinical remission at weeks 48 and 96, respectively. Furthermore, 133/217 (61.3%) and 128/217 (59.0%) patients had endoscopic improvement at weeks 48 and 96, while 72/217 (33.2%) and 78/217 (35.9%) patients attained endoscopic remission at weeks 48 and 96, respectively (Figure 2).”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.3-2"></a>

##### Primary outcome in the posted results: clinical remission at week 48 (of 217)

| Outcome | Participants |
| --- | --- |
| Clinical remission at week 48 | “119” |

Source: [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results)

<a id="topic-3.1.5.8.3-3"></a>

##### Secondary outcomes in the posted results: number of participants (of 217)

| Outcome | Week 48 | Week 96 |
| --- | --- | --- |
| Clinical response | “177” | “158” |
| Endoscopic improvement | “133” | “128” |
| Endoscopic remission | “72” | “78” |

Source: [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results)

<a id="topic-3.1.5.8.3-4"></a>

##### Week 48 and week 96 outcomes reported in the Form 20-F

> “At week 48, of those 217 patients who received a 50 mg once-daily oral dosing with obefazimod, 178 patients (82%) had clinical response, 119 patients (55%) were in clinical remission, 133 patients (61%) had endoscopic improvement and 72 patients (33%) had endoscopic remission.”
> “Of all 217 patients who entered the Phase 2b open-label maintenance trial, regardless of their status at the end of the 8-week induction period, 119 patients (55%) achieved clinical remission at week 48 and 114 patients (53%) achieved clinical remission at week 96.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.5.8.3-5"></a>

##### Outcomes by clinical response at week 8 of induction

> “Among the 124 patients with clinical response at week 8 of the induction trial, 82/124 (66.1%) and 74/124 (59.7%) achieved clinical remission at weeks 48 and 96, respectively (Figure 3).”
> “Among the 93 patients that did not achieve clinical response at week 8 of the induction trial, 37/93 (39.8%) and 40/93 (43.0%) achieved clinical remission at weeks 48 and 96, respectively.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.3-6"></a>

##### Outcomes by induction treatment: obefazimod or placebo

> “Overall, 162 patients treated with obefazimod during induction entered the OLM. Among this subgroup, 103/162 (63.6%) achieved clinical response at W8 of the induction trial, while 59/162 (36.4%) did not.”
> “For example, clinical remission was achieved by 69/103 (67.0%) and 65/103 (63.1%) among W8 clinical responders at W48 and W96, respectively, compared to 20/59 (33.9%) and 24/59 (40.7%) among W8 nonresponders.”
> “Among the 55 patients receiving placebo during induction and entering the OLM, 21/55 (38.2%) achieved clinical response at W8 of the induction trial, while 34/55 (61.8%) did not. Clinical remission was achieved by 13/21 (61.9%) and 9/21 (42.9%) of W8 clinical responders at W48 and W96, respectively, compared to 17/34 (50.0%) and 16/34 (47.1%) of nonresponders.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.3-7"></a>

##### Outcomes by previous biologic or JAK inhibitor exposure

> “Among the 98 patients with inadequate response to biologics (anti-TNFα, vedolizumab, ustekinumab) or JAK inhibitors, 74/98 (75.5%) achieved clinical response at week 48 and 66/98 (67.3%) at week 96; 38/98 patients (38.8%) were in clinical remission at both weeks 48 and 96 (Figure 4).”
> “Among the 119 patients naïve to biologics or JAK inhibitors at the induction study baseline, 103/119 (86.6%) and 92/119 (77.3%) achieved a clinical response at weeks 48 and 96. In this subset, clinical remission was achieved by 81/119 patients (68.1%) at week 48 and by 76/119 patients (63.8%) at week 96”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.3-8"></a>

##### Corticosteroid-free outcomes in participants receiving corticosteroids at induction baseline

> “Among the 115 patients enrolled in the OLM who received concomitant CS at induction baseline, 64/115 (55.7%) were in clinical remission rates at week 48 and 60/115 (52.2%) at week 96. While the protocol did not require CS-tapering upon entry to the OLM study, 12-week CS-free clinical remission was attained by 43/115 patients (37.4%) at week 48 and by 40/115 patients (34.8%) at week 96.”
> “Notably, among the patients that met clinical endpoints but not the corresponding CS-free clinical endpoints, many investigators chose not to attempt the optional CS-tapering.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.3-9"></a>

##### Fecal calprotectin

> “The median FCP concentration decreased from 204.7 µg/g at baseline of OLM, to 86.6 µg/g at week 48 and 89.6 µg/g at week 96 (Table 2). Of the 167 patients with available data at week 48, 122/167 (73.1%) achieved FCP levels below 250 µg/g, and 109/167 (65.3%) achieved FCP levels below 150 µg/g. At week 96, 102 (69.4%) of the 147 patients with available data achieved FCP levels below 250 µg/g, and 91/147 (61.9%) achieved FCP levels below 150 µg/g.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.3-10"></a>

##### miR-124 expression in blood and rectal tissue

> “Treatment with obefazimod 50 mg significantly enhanced the expression of miR-124 in blood and rectal tissue at weeks 48 and 96 (P < .001 vs. baseline) (Figure 6).”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.3-11"></a>

##### Comparison with week 8 induction results

> “Efficacy rates increased during the maintenance treatment period with obefazimod 50 mg relative to week 8 of the induction trial.”
> “At week 48 of the OLM study, these percentages increased to 82% for clinical response and 61% for endoscopic improvement.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="heading-3.1.5.8.4"></a>

#### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

##### IBDQ planned as a secondary endpoint in the protocol

> “Scores and changes from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) domains at week 24 and 48.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.8.4-2"></a>

##### Missing IBDQ scores not imputed in the statistical analysis plan

> “Missing Fecal calprotectin, CRP scores and IBDQ scores will not be imputed.”

Source: [Abivax ABX464-104 statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/SAP_001.pdf)

<a id="topic-3.1.5.8.4-3"></a>

##### Stool frequency subscore at weeks 48 and 96

> “The mean SFS decreased from 1.4 at OLM baseline to 0.7 at week 48 and 0.6 at week 96, with most patients having an SFS of 0 or 1 (87.9%) at week 96.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.4-4"></a>

##### Stool frequency and rectal bleeding recorded in a paper diary

> “Participants recorded stool frequency using a paper subject diary on a daily basis.”
> “Participants recorded rectal bleeding in a paper subject diary on a daily basis.”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="heading-3.1.5.8.5"></a>

#### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

##### Treatment-emergent adverse events over 96 weeks

> “At least 1 TEAE was reported for 148 (68.2%) of 217 obefazimod-treated patients (Table 3). The most common TEAEs reported in at least 5% of patients were COVID-19 (14.3%), headache (11.5%), UC (7.8%), nasopharyngitis (6.9%), back pain (5.5%), and arthralgia (5.1%). TESAEs were reported by 18 patients (8.3%).”
> “There was 1 malignant meningioma unrelated to treatment, and 1 death was reported, unrelated to treatment (car accident). TEAEs leading to study discontinuation were reported in 17 patients (7.8%) (Table 4). These events included the worsening of disease (coded as colitis ulcerative and colitis), which resulted in the discontinuation of 9 patients.”
> “Infections and infestations TESAEs, reported for 4 patients, comprised COVID-19/COVID-19 pneumonia (2 patients, 1.0%), urosepsis (1 patient, 0.5%), and appendicitis (1 patient, 0.5%).”
> “Laboratory results revealed no new or unexpected safety signals, and there were no clinically meaningful changes in laboratory parameters compared to week 8.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.5-2"></a>

##### Headache after switching dose at entry

> “Ten of the 25 patients who reported headache experienced them within the first 7 days after switching from placebo to obefazimod or from 25 to 50 mg upon entering the OLM study.”
> “Headache appears to be associated with the introduction to obefazimod treatment, as the rate was reduced to 11.5% of patients who received up to 96 weeks obefazimod 50 mg compared to 30.2% of patients who received obefazimod 50 mg during induction.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.5-3"></a>

##### Treatment-emergent adverse events leading to discontinuation

| Event | n (%) |
| --- | --- |
| Any TEAE | “17 (7.8)” |
| Colitis ulcerative | “7 (3.2)” |
| Colitis | “2 (0.9)” |
| Ischemic stroke | “1 (0.5)” |
| Left ventricular dysfunction | “1 (0.5)” |
| Alanine aminotransferase increased | “1 (0.5)” |

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.5-4"></a>

##### Adverse events in the posted results: participants affected / at risk (%)

| Event | ABX464 50 mg |
| --- | --- |
| All-cause mortality | “1/217 (0.46%)” |
| Serious adverse events, total | “18/217 (8.29%)” |
| Other adverse events, total | “148/217 (68.20%)” |
| COVID-19 | “31/217 (14.29%)” |
| Headache | “25/217 (11.52%)” |
| Colitis ulcerative | “17/217 (7.83%)” |
| Nasopharyngitis | “15/217 (6.91%)” |

Source: [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results)

<a id="topic-3.1.5.8.5-5"></a>

##### Long-term safety: phase 2b open-label maintenance study through 96 weeks

> “In total, 148/217 patients (68.2%) reported at least 1 treatment-emergent adverse event (TEAE).”
> “The most frequent TEAEs were COVID-19 (14.3%), headache (11.5%), UC (7.8%), and nasopharyngitis (6.9%).”
> “There was 1 malignant meningioma unrelated to treatment, and 1 death was reported, unrelated to treatment (car accident).”
> “AESIs reported in more than 1 patient were headache, rash, and eczema, which were reported in 4 (1.8%), 3 (1.4%), and 2 patients (0.9%), respectively.”
> “No new safety risks emerged over 96 weeks.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="heading-3.1.5.9"></a>

### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

#### Summary

ABX464-104 was a single-group, open-label study without a control group, in which all 217 participants received obefazimod 50 mg once daily regardless of their induction treatment or response; the investigators state that “the results must be interpreted with caution due to the absence of a control group”. Entry into the second year required clinical response at week 48, and 6 participants did not continue because they did not achieve it or were unwilling. Efficacy was analyzed with nonresponder imputation, and the statistical analysis plan carried forward week 48 results for completers missing a week 96 assessment. Corticosteroid tapering was recommended and not mandatory; the protocol defined glucocorticoid-free clinical remission as no glucocorticoids for at least 8 weeks before week 48, and the published analysis used cessation for at least 12 weeks. Endpoint definitions differ between documents: the registry's week 48 outcome defines clinical response as a reduction in Mayo score of at least 3 points, while its week 48 continuation criterion and the publication use at least 2 points; the registry adds an at least 1-point decrease in stool frequency subscore to the clinical remission definition. At week 48, 177 of 217 participants had clinical response in the publication and the posted results, and the Form 20-F reports 178 (82%). The registry's detailed description states a 48-week treatment period and its arm description states 96 weeks. Echocardiography was added by amendment after enrollment was complete, without drug-free baseline measurements. Participants were enrolled at 69 centers in 14 countries in Europe and Canada, race and ethnicity were not collected, and 10 participants discontinued for “Other reason (e.g., Ukraine Crisis)”. The protocol planned IBDQ assessment at week 24 and week 48, and no IBDQ results were located in the publication or the posted results. Abivax personnel designed the trial with the principal academic investigators, and Abivax analyzed the data.

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/); [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396); [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results); [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf); [Abivax ABX464-104 statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/SAP_001.pdf); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.5.9-2"></a>

#### Limitations stated by the investigators

> “Although the central evaluation of endoscopy data reduced the risk of bias in this open-label study, the results must be interpreted with caution due to the absence of a control group. Furthermore, steroid cycling was not accounted for in the NRI method, potentially limiting the interpretation of CS-free outcomes.”
> “CS-free efficacy rates might have been higher had CS-tapering been required during the OLM study.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.9-3"></a>

#### Role of the funder

> “Personnel from Abivax designed the trial in conjunction with the principal academic investigators. A contract research organization collected the trial data, Abivax analyzed the data, and all of the authors jointly interpreted the data.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
